BRIEF—FDA reminds pharma of new drug listing certification requirement

The deadline to update or certify companies’ drug listings with the US Food and Drug Administration, December 31, 2017, is fast approaching, the agency is warning the pharmaceutical industry.

This applies to drug listings that were not initially listed or updated during the current calendar year. This is the first deadline of the annual certification requirement under Part 207 of Title 21 of the Code of Federal Regulations.

Companies must submit this information to FDA in electronic format. They may make a blanket “no changes” certification to indicate that their listing information is up to date in FDA’s database. Information about how to certify or submit updates is available at Electronic Drug Registration and Listing System.

It is important for companies to update or certify their listings to ensure that FDA has an accurate list of marketed drugs in the National Drug Code directory, the agency stresses.

Failure to submit an update or certification by the December 31, 2017, deadline may result in FDA action, including removing the product from the NDC directory. Companies that need further assistance to submit the required information by the December 31, 2017, deadline should contact edrls@fda.hhs.gov.